Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03388138 · ClinicalTrials.gov registry record · Phase 2
Clinical Evaluation of Etafilcon A With Ketotifen
A Phase 2 study, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT03388138: Completed Phase 2 study, sponsored by Johnson & Johnson Vision Care.
NCT03388138 is a Phase 2 study that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 143 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03388138, a Phase 2 study, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
This clinical study is a randomized, double-masked, bilateral, controlled, two-arm parallel group, multi-site, 1-Week, 2-visit dispensing study. Subjects between the ages of 18-40 will be randomized into a placebo arm or an investigational K-Lens arm.
Primary Outcome
Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.
Interventions
- COMBINATION_PRODUCT etafilcon A with ketotifen
- DEVICE 1-Day ACUVUE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2017-12-06 |
| Est. Completion | 2018-02-09 |
| Phase | Phase 2 |
What the finished NCT03388138 record still lists
NCT03388138 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which etafilcon A with ketotifen is the first listed.
NCT03388138 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03388138 about?
NCT03388138 is a clinical study titled "Clinical Evaluation of Etafilcon A With Ketotifen". This clinical study is a randomized, double-masked, bilateral, controlled, two-arm parallel group, multi-site, 1-Week, 2-visit dispensing study. Subjects between the ages of 18-40 will be randomized into a placebo arm or an investigational K-Lens arm.
What is the current status of trial NCT03388138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2017-12-06. Estimated completion is 2018-02-09.
What interventions are being tested in trial NCT03388138?
The interventions under investigation include: etafilcon A with ketotifen (COMBINATION_PRODUCT), 1-Day ACUVUE (DEVICE).
Who is sponsoring clinical trial NCT03388138?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03388138's enrollment target sits among peer trials
143 507th of 2000 higher than 1,494 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI